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Varicose veins of the lower extremities occur in
approximately 20% of the adult population. The
dilated and tortuous superficial leg veins have abnor-
mal wall distensibility and valvular incompetence.
Direct measurements of venous pressure in limbs
with varicose veins show a lack of ambulatory venous
hypotension. Histologically, varicose veins have thin
media with variable orientation of smooth muscle
cells, increased fibrosis, and changes in composition
of extracellular matrix as compared with nonvaricose
veins.1-3 Previous studies from our laboratory and
from others also have identified distinct functional
differences in varicose veins when compared with
nonvaricose veins. Varicose veins showed decreased
responsiveness to neurotransmitters and endotheli-
um-derived vasoactive factors and activation of sec-
ond messenger systems like the cyclic nucleotides
(adenosine 5´-cyclic monophosphate [cAMP] and
guanosine 3´,5´-cyclic monophosphate [cGMP]).4-6
The metabolism of arachidonic acid by cyclooxygen-
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Objective: Experiments were designed to determine the production of prostacyclin and
thromboxane and the activation of cyclic nucleotides in human varicose and nonvaricose
veins and to determine whether these second messenger pathways were differentially
activated by the venotropic extract of Ruscus aculeatus.
Methods: The experiments were designed to characterize the activity of cyclic nucleotides
and the production of prostaglandins in human varicose and nonvaricose veins. Segments
of the greater saphenous veins and the adjacent tributaries were obtained from patients
who underwent vein stripping and excision of primary varicose veins. The saphenous
veins from the patients who underwent peripheral arterial bypass grafting were used as
controls. The segments of veins were incubated in Krebs-Ringer bicarbonate solution in
the presence of venotropic extract of Ruscus aculeatus (10–3 g/mL) or in water-miscible
organic solvent (dimethyl sulfoxide, 10–3 g/mL), for 1, 5, and 10 minutes at 37°C. The
nonspecific phosphodiesterase inhibitor (3-isobutyl-1-methylxanthine, 10–4 g/mL) was
used to block cyclic nucleotide degradation in some samples. Tissue and media samples
were collected. Tissue concentrations of both cyclic adenosine monophosphate and cyclic
guanosine monophosphate (cAMP and cGMP, respectively) and media concentrations of
6-ketoprostaglandin-F1a (the stable metabolite of prostacyclin) and thromboxane B2 (the
stable metabolite of thromboxane A2) were measured by means of radioimmunoassay.
Cyclooxygenase 2 was measured with Western blot analysis.
Results: The varicose veins showed greater levels of cAMP but not of cGMP at all time
points as compared with the control veins. Prostanoid production was not significantly
altered in the varicose veins. Stimulation with Ruscus aculeatus increased the cAMP concen-
tration in the varicose veins but did not affect the cGMP levels. The ratio between 6-keto-
prostaglandin-F1a and thromboxane B2 was two-fold greater in the varicose veins as com-
pared with the control veins. In the presence of the extract, the ratio of 6-ketoprostaglandin-
F1a and thromboxane B2 was identical in both types of veins. Cyclooxygenase 2 was not
present in either the control or the varicose veins.
Conclusion: These results suggest that cAMP levels are elevated in varicose veins and that
they can be altered with drug treatment in varicose veins. This chemical pathway may be
considered as a modulatory target to affect contraction with venotropic drugs. (J Vasc
Surg 1999;30:876-84.)
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ase, which results in the production of prostanoids,
also may differ in varicose veins as compared with
nonvaricose veins.7 Prostanoids affect contractile
function, proliferation of smooth muscle cells, and
adherence of platelets to the vascular wall.8-11
Therefore, the production of prostanoids has the
potential to impact on several characteristics of vari-
cose veins. The understanding of the relationships
between cyclic nucleotides and prostanoid produc-
tion in varicose veins may be important in the devel-
opment of venotropic agents. The routine therapeu-
tic approach for the treatment of primary varicose
veins is an invasive surgical procedure or sclerother-
apy, and the conservative options are limited because
no venotropic agents are approved in the United
States for the treatment of varicose veins.
In Europe, several compounds are available for
the treatment of venous insufficiency and lymphede-
ma.12-16 They contain, in part, an extract from the
root of Ruscus aculeatus.14,17,18 This plant is of the
family Liliaceae, found in the Mediterranean regions.
The extract contains many substances, including
chrysophanic acid, euparone, ruscogenin diglycoside,
and other steroidal saponins.19,20 The effects of these
compounds on vascular function have not been stud-
ied individually. However, the extract causes contrac-
tions of veins from humans and experimental animals
with the stimulation of at least three types of recep-
tors: adrenergic, muscarine, and endothelin.21-24 In
addition, Ruscus aculeatus extract reduces the uptake
and metabolism of norepinephrine by nonvaricose
and varicose veins.25
The purpose of this study was to characterize the
metabolites of arachidonic acid and the associated
changes in cyclic nucleotides in nonvaricose and
varicose veins and to determine the effects of an
extract of Ruscus aculeatus on these parameters. It
was hypothesized that production of prostanoids
and cyclic nucleotides would differ between nonvar-
icose and varicose veins and that they would be acti-
vated differently with Ruscus aculeatus extract.
MATERIALS AND METHODS
Veins were collected during the operation of 24
patients. Segments of the greater saphenous veins
and the adjacent tributaries were obtained from 17
patients (four men, 13 women; median age, 59
years; range, 32 to 85 years) who underwent vein
stripping and excision of primary varicose veins. All
the patients with primary varicose veins had greater
saphenous vein incompetence that was confirmed
with duplex scanning. The excess portions of saphe-
nous veins from seven patients (four men, three
women; median age, 66 years; range, 30 to 87 years)
who underwent peripheral arterial bypass grafting
were studied as control veins. The saphenous veins
for bypass grafting surgery were not tested for valvu-
lar incompetency. This protocol was approved by the
Institutional Review Board at the Mayo Clinic. All
the material was considered surgical waste and did
not require informed consent. The patient charac-
teristics are given in Table I.
The segments of the saphenous veins and the
varicose tributaries were excised before stripping and
handled gently to minimize the damage to the
endothelium and the smooth muscle. The control
veins were removed before the saphenous vein graft
was distended with papaverine hydrochloride solu-
tion. All the tissues were transported to the labora-
tory in a sterile physiologic solution (0.9% NaCl)
within 1 hour.
Experimental design
The veins were cleaned of connective tissue, cut
into 5-mm segments, placed in 3 mL of aerated
(95% 02, 5% CO2) modified Krebs-Ringer bicarbon-
ate solution (millimolar composition: NaCl, 118.3;
KCl, 4.7; CaCl2, 2.5; MgS04, 1.2; KH2P04, 1.2;
NaHC03, 25.0; calcium disodium edetate, 0.026;
and glucose, 11.1) in sets of glass test tubes, and
allowed to equilibrate at 37°C for 30 minutes. At
this time, the Krebs-Ringer bicarbonate solution was
exchanged with the same volume of fresh control
solution. In some experiments, 12 m L of 3-isobutyl-
1-methylxanthine (IBMX; 10–4 g/mL), a nonspecif-
Table I. Characteristics of patients
Patients with
Patient Control patients primary
characteristics (with nonvaricose veins) varicosity
No. of patients 7 17
Gender
Female 3 (42.8%) 13 (76.4%)
Male 4 (57.1%) 4 (23.5%)
Median age (range; y) 66.3 (30 to 87) 58.7 (32 to 85)
Family history 0 2 (11.7%)
Smoking history 3 (42.8%) 7 (41.1%)
Deep venous disease 0 0
Diabetes 1 (14.2%) 6 (35.2%)
Hypertension 2 (28.5%) 2 (11.7%)
Hyperlipidemia 2 (28.5%) 3 (17.6%)
Medication
Calcium channel blockers 2 (28.5%) 1 (5.8%)
Indomethacin 0 1 (5.8%)
Anesthesia
General 7 (100%) 13 (76.4%)
Epidural 0 4 (23.5%)
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ic inhibitor of phosphodiesterase activity, were
added and the tissues were incubated for an addi-
tional 30 minutes at 37°C. After these initial incu-
bations, the pairs of segments that were cut from the
same vein were treated either with the water-misci-
ble organic solvent (dimethyl sulfoxide; 10–3 g/mL)
or with Ruscus aculeatus extract (10–3 g/mL) for 1,
5, and 10 minutes at 37°C. Dimethyl sulfoxide is the
solvent for the Ruscus aculeatus extract. At each time
point, the tissues were removed and snap frozen in
liquid nitrogen and stored at –70°C for the subse-
quent measurement of cyclic nucleotides. The media
from the 10-minute incubation were also collected
and frozen at –70°C for the subsequent measure-
ment of prostanoids.
Measurement of cyclic nucleotide and protein
The frozen segments of veins were crushed
under liquid nitrogen and resultant powder homog-
enized in 1.0 mL of 6% cold trichloroacetic acid.
After centrifugation at 9000g for 20 minutes, super-
natants were taken and 30 m L were saved separately
for protein assay (bicinchoninic acid protein assay;
Pierce, Rockford, Ill), with bovine serum albumin as
the standard. After repeated washing of supernatants
with ethanol to remove lipids, the samples under-
went lyophilization, volume was restored, and the
concentrations of cAMP and cGMP were measured
with specific [125I]-radioimmunoassay kits.26
Measurement of prostanoids
The stable metabolite of prostacyclin, 6-keto-
prostaglandin-F1 a , and the stable metabolite of
thromboxane A2, thromboxane B2 (TBX2), were
measured in the media samples. The media concen-
trations were measured by means of [125I]-radioim-
munoassay.27
Measurement of cyclooxygenase 2. The seg-
ments of the control and the varicose veins were frozen
in liquid nitrogen, pulverized, and homogenized in 10
mmol/L Tris (hydroxymethyl) aminomethane, 1
mmol/L sodium orthovanadate, 1% sodium dodecyl-
sulfate (lauryl sulfate), and 100 m mol/L phenyl-
methylsulfonyl fluoride (pH 7.4). The tissue samples
then were centrifuged at 12,000g for 15 minutes at
4°C. Protein in the homogenate was measured with
bicinchoninic acid protein assay (Pierce, Rockford, Ill).
Protein (40 m g/lane) was separated on 7.5% sodium
dodecylsulfate–polyacrylamide gel with electrophore-
sis and was transferred to 0.45-m g pure nitrocellulose
membrane. The membrane was blocked with a 3%
blocking solution provided with the amplified Opti-
4CN substrate and detection kit (BioRad, Hercules,
Calif). The membrane was washed and immunoblot-
ted 16 hours with rabbit anti-human inducible
cyclooxygenase 2 polyclonal antiserum (1:1000
dilution; Caymen Chemical, Ann Arbor, Mich). A
goat–anti-rabbit horseradish peroxidase (BioRad)
was used as the secondary antibody. Detection with
the amplified Opti-4CN substrate produces a pur-
ple-colored signal visible on the blot. Molecular
mass was determined by comparison with biotinylat-
ed standards (high range, Bio-Rad) and cyclooxyge-
nase 2 (ovine) electrophoresis standard, which has a
molecular weight of 72 kD.
Calculation and statistic analysis
Data are expressed as picomoles per microgram
protein. Results are expressed as means ± the stan-
dard error of the mean. In each experimental condi-
tion, n represents the number of patients from
whom segments of veins were obtained.
The Student t test for unpaired data (two-tailed)
was used to assess statistical significance. Bonferroni
adjustment was used to correct for multiple com-
parisons when differences were identified between
groups. Statistical significance was accepted at a P
value of less than .05.
RESULTS
The tissue content of cAMP was significantly
greater in the varicose veins as compared with the
control veins after 10 minutes of incubation in solvent
solution (Fig 1). In the varicose veins, the accumula-
tion of cAMP was significantly less in the veins from
women (0.45 ± 0.31 pmol/m g protein in nine sam-
ples from four patients) as compared with the veins
from men (1.17 ± 0.45 pmols/m g protein in six sam-
ples from four patients). The tissue content of cGMP
was significantly less than that of cAMP in varicose
veins and was not significantly different between vein
types. The accumulation of cAMP and cGMP in vari-
cose veins was not significantly increased by incuba-
tion with IBMX (data not shown; n = 5).
There were no significant differences in the
accumulation of either 6-ketoprostaglandin-F1 a or
TBX2 between the control and the varicose veins
after 10-minute incubation in solvent solution (Fig
2). However, the ratio of 6-ketoprostaglandin-F1 a
to TBX2 was two-fold higher in the varicose veins as
compared with the control veins (the ratio was 4.1
in control veins and 10.1 in varicose veins).
Effect of the venotropic agent
cAMP did not change significantly in either the
control or the varicose veins during the 10-minute
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incubation period with Ruscus aculeatus (Fig 3). At
1 minute, there was a 33.4% increase in the mean
cAMP in the varicose veins as compared with a 33%
decrease in the mean cAMP in the control veins that
were incubated with the extract.
The accumulation of cGMP was not altered sig-
nificantly by incubation with the extract in either
type of vein at any of the time points studied (data
not shown; n = 5 for control veins and n = 10 for
varicose veins). The accumulation of cGMP was not
increased significantly with the incubation of vari-
cose veins in IBMX (data not shown; n = 5).
After 10 minutes of incubation with Ruscus
aculeatus extract, there were no statistically signifi-
Fig 2. Production of 6-ketoprostaglandin-F1 a and thromboxane B2 in solvent solution
(dimethyl sulfoxide, 10–3 g/mL) from control veins and varicose veins. Data are shown as
mean ± standard error of mean, and n equals number of patients. After 10 minutes of incuba-
tion in solvent solution, there were no significant differences in production of 6-keto-
prostaglandin-F1a or thromboxane B2. 
Fig 1. Concentrations of cyclic adenosine monophosphate (cAMP) and cyclic guanosine
monophosphate (cGMP) in control and varicose veins after 10 minutes incubation in solvent
solution. Accumulation of cAMP in varicose veins was significantly increased as compared with
that in control veins. Content of cGMP was low and not statistically different between two
types of veins. Data are shown as mean ± standard error of mean, and n equals number of
patients from whom veins were taken.
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cant increases in either 6-ketoprostaglandin-F1 a or
TBX2 (Fig 4). However, the ratio of 6-keto-
prostaglandin to TBX2 became similar (5.9 for vari-
cose veins and 6.7 for control veins).
Expression of cyclooxygenase 2
No precipitate was visible on the Western blot at
72 kD, corresponding to the standard for cyclooxy-
genase 2 in the samples from either the control 
or the varicose saphenous veins. However, differ-
ences in the bands were visible at close to 66 kD and
at 45 kD (Fig 5).
DISCUSSION
The major finding of this study was that the accu-
mulation of the cyclic nucleotide cAMP is greater 
in varicose veins as compared with control nonvari-
cose veins. It is unclear whether or not this increase 
in cAMP content of varicose veins is the result 
of increased production (ie, activity of adenylate
cyclase) or slower breakdown with phosphodiesteras-
es. Because the incubation of the tissue with the non-
selective inhibitor of phosphodiesterase did not in-
crease the accumulation of cAMP in the varicose
veins, it is more likely that the cAMP increase is the
result of increased production. cAMP may be stimu-
lated by prostacyclin in vascular smooth muscle.28
Although there were no statistically significant differ-
ences in the concentrations of prostacyclin (as mea-
sured with 6-ketoprostaglandin-F1a ) in the varicose
and nonvaricose veins, the ratio of prostacyclin to
thromboxane A2 was greater in the varicose veins than
in the nonvaricose veins and could explain, in part,
the increased levels of cAMP in the varicose tissue.
Indeed, the incubation of cultured smooth muscle
cells from human saphenous veins with prostacyclin-2
and interleukin-1 increased cAMP.28 In cultured cells,
as in this study, the increases in cAMP were not 
sustained, even in the presence of inhibition of phos-
phodiesterases. Also consistent with findings from
cultured smooth muscle derived from human saphe-
nous veins, the cGMP levels were low.6,28 The low
concentrations of cGMP in the varicose veins are con-
sistent with observations that relaxations to the
endothelium-derived factor nitric oxide are reduced
in varicose veins as compared with nonvaricose veins.4
Relaxations to nitric oxide are mediated in part
through the accumulation of cGMP in the smooth
muscle.29,30 Therefore, reduced relaxations to nitric
oxide in the varicose veins as compared with the non-
varicose veins may reflect differences in regulatory
pathways associated with cGMP. Whether or not
there are defects in transcriptional or post-translation-
al synthesis of enzymes associated with cGMP pro-
duction or degradation, as has been found for colla-
gen type III and fibronectin in varicose veins,1
remains to be determined.
Whether or not differences in the accumulation of
cyclic nucleotides represents a primary or secondary
defect in varicose disease also remains to be deter-
mined. The changes in prostacyclin, and subsequently
cAMP, may act to modulate smooth muscle prolifera-
tion in varicose veins9,10 and, if secreted into the
lumen of the veins, could alter platelet aggregation.11
Fig 3. Effects of Ruscus aculeatus on production of cyclic adenosine monophosphate in con-
trol and varicose veins. Data are shown as mean ± standard error, and n equals number of
patients from whom veins were taken.
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As stated previously, the ratio of prostacyclin to
thromboxane A2 was greater in the varicose veins than
in the nonvaricose veins. Prostacyclin is derived from
the metabolism of arachidonic acid by cyclooxyge-
nase. Cyclooxygenase is constitutively expressed
(cyclooxygenase 1) or can be induced (cyclooxygen-
ase 2) by mechanical damage, oxidative stress, and
proinflammatory cytokines.31 Cyclooxygenase 2 is
not expressed in human saphenous veins harvested for
coronary artery bypass grafting but is induced when
the veins are incubated in organ culture.31 As expect-
ed, cyclooxygenase 2 was not present in the control
saphenous veins in this study nor was the enzyme pre-
sent in the varicose veins. Therefore, the differences in
the enzymes downstream of cyclooxygenase may 
differ in the varicose veins as compared with the non-
varicose veins. For example, when the veins were
incubated with the cyclooxygenase product cyclic
endoperoxide H2, the production of prostacyclin in
the varicose veins was greater than in the nonvaricose
veins, which suggests that the activation of prostacy-
clin synthase may be different in the two types of
veins.7
The polyclonal antibody that was used to detect
cyclooxygenase 2 in this study identified several
other proteins in both the control and the varicose
veins. The differences in density were observed at
about 66 kD and 45 kD. These bands represented
other proteins differentially expresssed in varicose
veins as compared with control veins, and their iden-
tity remains to be determined.
A limitation of this study is that the tissues were
obtained from patients with ongoing cardiovascular
disease. Indeed, gender, hypertension, anesthesia,
calcium channel blockade, and other risk factors for
cardiovascular disease could all potentially affect the
baseline and the stimulated accumulation of cyclic
Fig 4. Effect of Ruscus aculeatus on production of 6-ketoprostaglandin-F1a and thrombox-
ane B2 in control veins and varicose veins. Prostanoid concentration was measured in incuba-
tion solution after 10 minutes’ exposure to either solvent (dimethyl sulfoxide) or Ruscus
aculeatus (10–3 g/mL). Data are shown as mean ± standard error of mean, and n equals the
number of patients from whom veins were taken. 
Fig 5. Western blot analysis results of control and varicose
saphenous veins with polyclonal antibody against synthetic
peptide from human cyclooxygenase 2 sequence conjugat-
ed to bovine serum albumin. Lanes 1 to 3 represent samples
from control, nonvaricose saphenous veins. Lanes 4 to 6
represent samples from varicose tributaries. Lane 7 repre-
sents electrophoresis ovine cyclooxygenase 2 standard, and
lane 8 represents biotinylated standards. No bands were
present in any sample at weight corresponding to standard
for cyclooxygenase 2 (72 kd). However, differential posi-
tive signals were observed at about 66 kD and 45 kD.
nucleotides. These factors probably contributed to
the large variability in the baseline concentrations of
cAMP and prostanoids in the varicose veins. The
veins from the patients who underwent peripheral
arterial bypass grafting had ongoing arterial disease.
How this impacts on venous function has not been
studied systematically. It may be suggested that the
veins that do not show abnormalities—that is, non-
varicose veins from patients with varicose disease—
may be a better control tissue. However, the con-
tractions of greater saphenous veins (not showing
structural abnormalities) may be reduced as com-
pared with veins from patients for bypass grafting4
and may not be representative of true nonvaricose
tissue. Gender and sex steroid hormones may also
contribute to the variability in the accumulation of
cyclic nucleotides and prostanoid production. In
varicose tissue, the accumulation of cAMP was less
in the tissue from women as compared with the tis-
sue from men. The data that would enable the cor-
relation of those values to hormonal status are not
available.
Extract of Ruscus aculeatus is used in the treat-
ment of varicose veins, venous insufficiency, and
lymphedema in Europe.12,17,18 The active compo-
nents of Ruscus aculeatus extract include chryso-
phanic acid, euparone, and steroidal saponins.19,20
Ruscus aculeatus extract causes the contraction of
varicose veins, but not nonvaricose veins, through
the activation of alpha-adrenergic, endothelin-1, and
muscarinic receptors.21,22 In this study, although the
release of both prostacyclin and thromboxane A2
tended to increase in both the control and the vari-
cose veins when incubated with the extract, cAMP
tended to increase only in the varicose veins. How
this increase in cAMP is associated with the contrac-
tion of varicose veins remains to be determined.
Prostacyclin causes the relaxation or the contraction
of human varicose veins and veins from experimen-
tal animals, depending on the level of the pre-exist-
ing tone.4,5,32 Alternatively, changes in cAMP may
reflect receptor-coupled modulation with guanine
nucleotide regulatory proteins, which either stimu-
late or inhibit adenylate cyclase (Gs and Gi proteins,
respectively). Subsequently, the activation of cAMP-
dependent protein kinases and the translocation of
its catalytic subunit to the nucleus stimulates the
activity of the transcriptional regulators33 associated
with cytostatic cell functions.20
In summary, results of this study identify differ-
ences in the regulation of cAMP in varicose veins as
compared with nonvaricose veins. This intracellular
second messenger system is associated with the con-
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traction and proliferation of vascular smooth muscle
and the promoter regions of genes. All of these func-
tions may be associated with changes in venous
structure that characterize varicose veins. Therefore,
the regulation of cAMP may represent a potential
biochemical target in the development of venotrop-
ic drugs.
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Dr Ronald L. Dalman (Stanford, Calif). The preva-
lence of venous disease makes the possibility of drug ther-
apy, as a practical alternative to surgical stripping, scle-
rotherapy, or ligation, very attractive. Last year’s American
Venous Forum program included preliminary work from
France that speculated on the role of collagen metabolism
in venous disease, implying a therapeutic role for the regu-
lation of matrix metalloproteins or their inhibitors and the
treatment or prevention of varicose veins. Dr Nemcova and
her associates have now focused our attention on the reg-
ulation of second messengers, such as cyclic AMP, to
achieve similar goals through different mechanisms. At this
meeting in 1992, the vascular physiology group at Mayo,
including Drs Gloviczki and Miller, reported on the results
of organ chamber strain gauge comparisons between con-
trol and varicose veins taken from patient cohorts similar to
those described in the current report. They have updated
the series by comparing tissue and media concentrations of
both cyclic adenosine and guanosine monophosphate in
media concentrations of stable metabolites of prostacyclin
and thromboxane A2 from these groups. In addition, vein
samples were incubated with Ruscus aculeatus extract used
as venotropic therapy in Europe or organic solvent alone.
A nonspecific phosphodiesterase inhibitor was used to
block cyclic nucleotide degradation in some samples.
Despite relatively small sample sizes in each group, tissue
content of cyclic AMP was significantly greater in varicose
veins as compared with control veins after 10-minute incu-
bation in solvent solution. Accumulation was not signifi-
cantly increased after incubation with phosphodiesterase
inhibitor. No similar differences were noted in cyclic GMP.
These observations lead to the first question. Because
Ruscus aculeatus appears to increase cyclic AMP produc-
tion and apparently cyclic AMP is related to vasorelaxation,
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yet the Ruscus aculeatus extract seems to cause contraction
of the varicose veins, perhaps the authors can elaborate on
the mechanism of Ruscus aculeatus as venotropic therapy?
Is veno constriction mediated through the endothelin
receptor interactions that were previously described?
My second question is, as noted in Table I, there are
potentially significant differences in the control and study
groups. For example, gender and the incidence of hyper-
tension, diabetes, and hyperlipidemia are different between
the two groups. Also, a quarter of the control patients were
taking calcium channel blockers versus 6% of the study
group. The type of anesthesia provided during harvest was
also different between the groups, that being general ver-
sus spinal anesthesia at the time of harvest. How might
hypertension, gender, and calcium channel blockade along
with these other factors impact baseline or inducible levels
of cyclic AMP as noted between the two groups?
In Fig 3 in the manuscript, the accumulation of cyclic
AMP in response to the Ruscus aculeatus extract clearly dis-
tinguished the varicose vein and the control vein popula-
tions. However, significant increases in cyclic AMP from
varicose veins were also noted after incubations with solvent
alone. It may be that there was some confusion about the
time points on that graph, but I am curious if there was an
effect of the solvent alone on cyclic AMP accumulation and
varicose veins?
Finally, the authors have noted in the manuscript that
the differences in the intracellular messenger, such as
cyclic AMP in varicose veins as compared with cyclic AMP
in healthy veins, may provide the potential therapeutic tar-
gets for pharmaceutic therapies.
Given the demonstrated defects in response to con-
tractile and relaxation stimuli, can the authors speculate as
to how, in particular, modifying levels of cyclic AMP may
prove useful in the treatment of varicose veins?
The manuscript includes one 10-year-old reference from
a peer-reviewed journal that reported improved patient sub-
jective response to venotropic therapy including Ruscus
aculeatus extract. Are the authors aware of other studies
including this agent or other sympathomimetic or other con-
tractile agents in the clinical treatment of venous varicosities?
In the long and distinguished tradition of the vascular
physiology group at the Mayo Clinic, the manuscript pre-
pared by Dr Nemcova is succinct, focused, and well written.
It was a pleasure to read and review. I thank the Society for
the privilege of discussing this potentially important contri-
bution to the understanding of the pathophysiology of
venous disease.
Thank you.
Dr Simona Nemcova. Contractions to Ruscus aculeatus
may be mediated through the stimulation of at lease three
types of receptors: adrenergic, muscarinic, and endothelin
(Gen Pharmacol 1983;14:227-83; Gen Pharmacol 1984;
15:103-6).21,22 Ruscus aculeatus also affects the uptake and
metabolism of norepinephrine (Phlebology 1988;3(Suppl
1):33-9). Ruscus aculeatus is an extract that contains many
substances, including chrysophanic acid, euparone, rusco-
genin diglycoside.19,20 The effects of these compounds on
vascular function have not been studied individually. It does
appear contradictory that Ruscus aculeatus causes increases
in cyclic AMP and contraction in varicose veins when the
cyclic nucleotide is usually associated with relaxation.
However, increased cyclic AMP in varicose veins is consis-
tent with greater amounts of prostacyclin in varicose as
compared with control veins. Prostacyclin has been report-
ed to cause contraction of varicose veins.4,5 The relationship
between the accumulation of cyclic AMP and the regulation
of intracellular calcium in varicose veins to our knowledge
has not been defined.
Indeed, gender, hypertension, anesthesia, calcium
channel blockade, and other risk factors for cardiovascular
disease could all potentially affect baseline and stimulated
accumulation of cyclic nucleotides. These factors probably
contribute to the large variability in baseline concentra-
tions of cyclic AMP and prostanoids in the varicose veins
from patients undergoing coronary or peripheral arterial
bypass grafting who have ongoing arterial disease. How
this impacts on venous function has not been studied sys-
tematically. Nonvaricose veins from patients with varicose
disease may be a better control tissue. However, decreased
contractions of greater saphenous veins (not showing
structural abnormalities) may be reduced compared with
veins from patients for bypass grafting.4
The solvent for time controls and Ruscus aculeatus
was dimethyl sulfoxide. Dimethyl sulfoxide may affect the
accumulation of cyclic AMP. Unfortunately, experiments
with time controls in the absence of dimethyl sulfoxide
were not included as part of this study.
It is not clear at this time whether or not the greater
accumulation of cyclic AMP in varicose veins represents a
cause or an adaptive response that limits the progression of
the varicose disease. Alternatively, some of the bioflavinoids
in the extract may act as phosphodiesterase inhibitors or
cytostatic agents.
Other clinical studies report the effects of Ruscus
aculeatus and other components in the extract (Angio-
logy 1997;48:958-63; Clin Hemorheol 14, suppl,
1994).13,14,21,22
